HY
HYPMY.US Hypera SA
- Market cap
- USD 2.77B
- P/E
- 7.6x
- P/B
- 1.05x
- ROE
- 12.2%
- Dividend yield
- 5.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is HYPMY.US undervalued?
Graham numberHYPMY.US trades 40.6% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hypera SA fundamental analysis
No fundamental analysis for Hypera SA yet.
Hypera SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under A…
Full company profileHypera SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hypera SA annual financial statements (BRL; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.29B | 3.64B | 3.72B | 3.29B | 4.09B | 5.94B | 7.55B | 7.91B | 7.44B | 7.70B | 9.06B |
| Gross Profit | 2.44B | 2.71B | 2.67B | 2.09B | 2.63B | 3.80B | 4.76B | 5.00B | 4.38B | 4.55B | 5.40B |
| Operating Income | 1.07B | 1.16B | 1.23B | 1.09B | 1.40B | 2.04B | 2.64B | 2.29B | 1.80B | 1.74B | 2.52B |
| EBITDA | 1.14B | 1.36B | 1.37B | 1.26B | 1.54B | 2.16B | 2.77B | 2.88B | 2.23B | 2.26B | 2.85B |
| Net Income | 1.18B | 965M | 1.13B | 1.16B | 1.30B | 1.33B | 1.70B | 1.65B | 1.34B | 1.20B | 1.82B |
| EPS | 1.84 | 1.52 | 1.77 | 1.82 | 2.03 | 2.08 | 2.65 | 2.58 | 2.10 | 1.88 | 2.58 |
| Balance Sheet | |||||||||||
| Total Assets | 11.5B | 10.1B | 10.6B | 11.9B | 17.2B | 19.8B | 23.8B | 24.5B | 24.6B | 25.2B | 30.2B |
| Total Liabilities | 2.67B | 2.39B | 2.29B | 3.21B | 8.01B | 9.98B | 13.1B | 13.0B | 12.5B | 12.6B | 15.3B |
| Shareholders' Equity | 8.81B | 7.74B | 8.27B | 8.71B | 9.24B | 9.83B | 10.6B | 11.5B | 12.1B | 12.5B | 14.9B |
| Cash & Short-term Investments | 1.35B | 1.52B | 1.65B | 2.25B | 4.74B | 2.29B | 2.86B | 2.58B | 1.74B | 1.65B | 2.07B |
| Total Debt | 908M | 676M | 582M | 1.45B | 5.59B | 7.41B | 9.68B | 9.96B | 9.40B | 9.34B | 7.90B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 882M | 933M | 1.07B | 824M | 1.18B | 1.40B | 2.04B | 2.40B | 2.54B | 2.57B | 2.06B |
| Capital Expenditure | 214M | 212M | 221M | 362M | 1.93B | 839M | 1.51B | 813M | 772M | 799M | 468M |
| Free Cash Flow | 668M | 721M | 846M | 462M | -744M | 560M | 529M | 1.58B | 1.77B | 1.78B | 1.59B |
| Ratios | |||||||||||
| ROE | 13.4% | 12.5% | 13.7% | 13.4% | 14.0% | 13.5% | 15.9% | 14.3% | 11.1% | 9.5% | 12.2% |
| ROA | 10.3% | 9.5% | 10.7% | 9.8% | 7.5% | 6.7% | 7.1% | 6.7% | 5.5% | 4.8% | 6.0% |
| Net Profit Margin | 35.8% | 26.5% | 30.3% | 35.3% | 31.7% | 22.4% | 22.5% | 20.8% | 18.0% | 15.5% | 20.1% |
| Debt to Equity | 0.10x | 0.09x | 0.07x | 0.17x | 0.61x | 0.75x | 0.91x | 0.87x | 0.78x | 0.75x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hypera SA dividends
- Dividend yield
- 5.14%
- Forward dividend
- 0.20 USD
- Payout ratio
- 52.5%
- Ex-dividend date
- Oct 5, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | BRL 628M | 0.99 | 52.5% |
| 2024 | BRL 787M | 1.23 | 58.7% |
| 2023 | BRL 760M | 1.19 | 46.1% |
| 2022 | BRL 806M | 1.26 | 47.5% |
| 2021 | BRL 746M | 1.17 | 56.1% |
| 2020 | BRL 682M | 1.07 | 52.7% |
| 2019 | BRL 623M | 0.97 | 53.6% |
| 2018 | BRL 633M | 0.99 | 56.0% |
| 2017 | BRL 410M | 0.64 | 42.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Hypera SA
Ownership data of Hypera SA is not available yet.
Hypera SA company profile
- Company name
- Hypera SA
- Ticker
- HYPMY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10,564
- Fiscal year end
- December
- Address
- Av. Magalhães de Castro, 4800, São Paulo, SP, Brazil, 05676-120
- Phone
- 55 11 3627 4206
- Website
- hypera.com.br
About Hypera SA
Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptics products under Merthiolate brand; Herbal medicine products under Maracugina, Eparema, Tamarine, and Naturetti brands; gastrointestinal products under Dramin, Estomazil, Engov, Lacto-purga, gastrol, Epocler, Bifilax, and Pepsamar brands. In addition, the company provides generics products under neo quimica brand; skicare products under episol, epidrat, simple organic, and bioage brands; supplements and vitamins products Addera, Biotonico Fontoura, Colflex, and Vitasay brands; and other products under Nebacetin, Cepacol, ESCABIN, Mirrorelax, Ammy, Nesina, and Diprospan brands. The company was formerly known as Hypermarcas S.A. and changed its name to Hypera S.A. in February 2018. Hypera S.A. was founded in 1999 and is headquartered in São Paulo, Brazil.
Hypera SA management
6- Mr. Breno Toledo Pires de OliveiraChief Executive Officer · born 1975
- Mr. Ramon Sanches Frutuoso SilvaCFO & Investor Relation Officer · born 1987
- Mr. Rafael Vito BatistaChief Operations Officer · born 1985
- Mr. Luiz Eduardo Sales ClavisVice President of Commercial & Marketing · born 1971
- Mauricio ChristovamSenior Human Resources Officer
- Mr. Hélio SegourasHead of Consumer Health